Phase I clinical study on the safety, tolerability, pharmacokinetics and pharmacodynamics of KL-A167 injection in patients with relapsed or refractory malignant lymphoma
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Tagitanlimab (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- 17 Jan 2025 New trial record